Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia

NCT03697707 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia in Remission

Interventions

BIOLOGICAL: DCP-001

Sponsor

Mendus

Collaborators

[object Object]